Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.40 |
| ▸ | HBB | P68871 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29716235 | 0.95 | MEN1 (0.47) | MAOBMAOACYP1A2CYP2C19SMN1; SMN2 | |
| SCHEMBL22009628 | 0.95 | MEN1 (0.47) | MAOBMAOACYP1A2CYP2C19SMN1; SMN2 | |
| SCHEMBL22009627 | 0.85 | KDM4E (0.44) | SMN1; SMN2LMNAKDM4EMEN1KMT2A | |
| SCHEMBL29716171 | 0.85 | KDM4E (0.44) | SMN1; SMN2LMNAKDM4EMEN1KMT2A | |
| SCHEMBL15533745 | 0.82 | TP53 (0.53) | CYP1A2CYP2C19SMN1; SMN2KDM4EMEN1 | |
| SCHEMBL1201346 | 0.81 | CYP3A4 (0.44) | CYP2C19LMNAHTTKDM4EMEN1 | |
| SCHEMBL16659211 | 0.81 | ALDH1A1 (0.40) | SMN1; SMN2LMNAKDM4EMEN1KMT2A | |
| SCHEMBL21190857 | 0.79 | MAOB (0.43) | MAOBMAOASMN1; SMN2LMNAHTT | |
| SCHEMBL30127171 | 0.79 | SMN1; SMN2 (0.56) | MAOBMAOACYP1A2CYP2C19SMN1; SMN2 | |
| SCHEMBL21572248 | 0.79 | MEN1 (0.56) | CYP1A2CYP2C19SMN1; SMN2KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250214948-A1 | TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS | AlzeCure Pharma AB (SE) | 2025-07-03 | — | — | US | disclosed |
| CN-111819172-B | Triazine derivatives for the treatment of neurotrophin related diseases | 阿泽克制药公司 | 2024-02-06 | — | — | CN | disclosed |
| EP-3759088-B1 | TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS | AlzeCure Pharma AB (SE) | 2023-01-25 | — | — | EP | disclosed |
| US-20220306589-A1 | TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS | AlzeCure Pharma AB (SE) | 2022-09-29 | — | — | US | disclosed |
| US-11352332-B2 | Triazine derivatives for treating diseases relating to neurotrophins | AlzeCure Pharma AB (SE) | 2022-06-07 | — | — | US | disclosed |
| EP-3759088-A1 | TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS | Alzecure Pharma AB (SE) | 2021-01-06 | — | — | EP | disclosed |
| US-20200399230-A1 | TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS | AlzeCure Pharma AB (SE) | 2020-12-24 | — | — | US | disclosed |
| CN-111819172-A | Triazine derivatives for the treatment of neurotrophin-related disorders | 阿泽克制药公司 | 2020-10-23 | — | — | CN | disclosed |
| WO-2019162702-A1 | TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS | AlzeCure Pharma AB (SE) | 2019-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220306589-A1 | TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS | NTRK2, BDNF, NGF | MAOB 104/4885MAOA 126/4885CYP1A2 2565/4885 |
| US-20250214948-A1 | TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS | NTRK2, BDNF, NGF | MAOB 104/4885MAOA 126/4885CYP1A2 2565/4885 |
| US-11352332-B2 | Triazine derivatives for treating diseases relating to neurotrophins | NTRK2, BDNF, NGF | MAOB 69/4885MAOA 96/4885CYP1A2 2171/4885 |
| US-20200399230-A1 | TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS | NTRK2, BDNF, NGF | MAOB 69/4885MAOA 96/4885CYP1A2 2171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.